Israel Cancer Association - Annual Report 2024

Israel Cancer Association // Annual Report 2024

Name of researcher

Institution

Researche subject

Prof. Raanani, Pia

Rabin Medical Center

Repurposing of the iron chelator deferasirox to overcome venetoclax resistance in mantle cell lymphoma via downregulation of MCL1 Utilizing FAPI PET/CT for Staging of early-stage, node positive, Invasive Lobular Breast cancer Elucidating the role of Stromal Fibroblasts in remodeling MRI Background Parenchymal Enhancement and the underlying effect on Breast Carcinogenesis Combinatorial immune-therapeutic approaches to target neoantigen-positive lung cancer Overcoming Anti-GD2 Immunotherapy Resistance using Epitranscrpitomic Inhibition – Neuroblastoma As a Proof of Concept Identification of immune checkpoint-inhibitor (CPI) induced Patient-Derived Antibodies Against NSCLC Symptoms related to sexuality and intimacy and educational needs of Israeli Hemato-Oncology patients and Heath Care Professionals' knowledge, attitudes and practice (KAP): A correlational interventional study Development of an Algorithm for Predicting and Preventing Deterioration in Cancer Patients: A Personalized Approach in Oncology Nursing N-VEGF - a new target for cancer anti-angiogenic therapy Blood-arachnoid barrier disruption in patients with leptomeningeal disease: A blood biomarkers study

Dr. Eshet, Yael

Sheba Medical Center Sheba Medical Center

Dr. Dadiani, Maya

Prof. Berger, Michael

Hebrew University Enhancing T Cell Function Through Ant2 Inhibition for Improved Cancer Immunotherapy

Prof. Samuels, Yardena

Weizmann Institute of Science

Dr. Grossman, Liron

Sheba Medical Center

Prof. Bar, Jair

Sheba Medical Center

Dr. Shifran-Tikva, Sigal

Hadassah Ein Kerem Medical Center

Dr. Bar-Lev, Shirley

Ruppin Academic Center

Dr. Reizel, Yitzhak

Technion

Prof. Mardor, Yael

Sheba Medical Center

44